Fig. 3: Results of probabilistic sensitivity analysis using a limited healthcare perspective and $5000 cost of PAT. | Translational Psychiatry

Fig. 3: Results of probabilistic sensitivity analysis using a limited healthcare perspective and $5000 cost of PAT.

From: Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis

Fig. 3

The graphs in this figure summarize the results of the probabilistic analyses from a limited healthcare perspective and assuming a $5000 cost of PAT. Cost-effectiveness acceptability curves (A) display the probability that each intervention is cost-effective over a range of cost-effectiveness thresholds. The probabilities are calculated based on the results of the 1000 simulations. Expected loss curves (B) plot the per-person cost (or forgone benefits) of choosing an intervention if it is suboptimal. The intervention with the lowest expected loss at any cost-effectiveness threshold is the optimal choice. The cost-effectiveness threshold where the curves cross is equal to the expected incremental cost-effectiveness ratio of PAT. The gray horizontal band represents the conventional cost-effectiveness threshold range used in the US ($100,000–150,000 cost per QALY gained). PAT psilocybin-assisted therapy, QALY quality-adjusted life year.

Back to article page